Cargando…
A simplified cell-based assay to identify coronavirus 3CL protease inhibitors
We describe a mammalian cell-based assay capable of identifying coronavirus 3CL protease (3CLpro) inhibitors without requiring the use of live virus. By enabling the facile testing of compounds across a range of coronavirus 3CLpro enzymes, including the one from SARS-CoV-2, we are able to quickly id...
Autores principales: | Resnick, Samuel J., Iketani, Sho, Hong, Seo Jung, Zask, Arie, Liu, Hengrui, Kim, Sungsoo, Melore, Schuyler, Nair, Manoj S., Huang, Yaoxing, Tay, Nicholas E.S., Rovis, Tomislav, Yang, Hee Won, Stockwell, Brent R., Ho, David D., Chavez, Alejandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457602/ https://www.ncbi.nlm.nih.gov/pubmed/32869020 http://dx.doi.org/10.1101/2020.08.29.272864 |
Ejemplares similares
-
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2020) -
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2021) -
Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2021) -
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19
por: Liu, Hengrui, et al.
Publicado: (2022) -
Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites
por: Iketani, Sho, et al.
Publicado: (2022)